These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection. Roder C; Athan E Drugs R D; 2020 Sep; 20(3):209-216. PubMed ID: 32377889 [TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Abutaleb NS; Seleem MN Sci Rep; 2021 Mar; 11(1):7093. PubMed ID: 33782498 [TBL] [Abstract][Full Text] [Related]
5. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. AbdelKhalek A; Abutaleb NS; Mohammad H; Seleem MN Int J Antimicrob Agents; 2019 Jan; 53(1):54-62. PubMed ID: 30273668 [TBL] [Abstract][Full Text] [Related]
6. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections. Abutaleb NS; Seleem MN Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253206 [No Abstract] [Full Text] [Related]
7. Antimicrobial Activity of Tannic Acid Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806 [TBL] [Abstract][Full Text] [Related]
8. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection. Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM mBio; 2020 Mar; 11(2):. PubMed ID: 32156806 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile. Johnstone MA; Holman MA; Self WT Sci Rep; 2023 Sep; 13(1):14733. PubMed ID: 37679389 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model. Chilton CH; Crowther GS; Miossec C; de Gunzburg J; Andremont A; Wilcox MH J Antimicrob Chemother; 2020 Jun; 75(6):1458-1465. PubMed ID: 32097465 [TBL] [Abstract][Full Text] [Related]
12. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. Aldape MJ; Heeney DD; Bryant AE; Stevens DL J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model. Yang J; Meng L; Yang H Microbiol Spectr; 2022 Apr; 10(2):e0067222. PubMed ID: 35311540 [TBL] [Abstract][Full Text] [Related]
14. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130 [TBL] [Abstract][Full Text] [Related]
15. Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model. Buckley AM; Altringham J; Clark E; Bently K; Spittal W; Ewin D; Wilkinson V; Davis G; Moura IB; Wilcox MH J Antimicrob Chemother; 2021 Jan; 76(1):171-178. PubMed ID: 32929459 [TBL] [Abstract][Full Text] [Related]
17. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence. Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467 [TBL] [Abstract][Full Text] [Related]